Biotech Values

[jq1234]

His article was written in early 2012, published on March 2012 in Blood. Jakafi survival data came at ASH2012. You can't complain about that part too much.

Anyway, I would agree he was generally a little TOO negative on Jakafi. I bought INCY after his first negative letter published which caused sell off before approval. He was somewhat right in his criticism of Jakafi side effect early on though (now we know mostly due to too aggressive dosing schedule), and generally correct in guiding CYT387 to more appropriate dosing schedule. So it is not all bad.